PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Orbus Therapeutics, Inc., a private pharmaceutical company, today announced that the combination of eflornithine and lomustine achieved a ...

Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine ...

Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, ... · ACCESS Newswire · CNS Pharmaceuticals, Inc. "Berubicin is being ...

Please provide your email address to receive an email when new articles are posted on . The addition of lomustine to bevacizumab failed to confer a survival advantage for the treatment of progressive ...

Review the side-effects of Lomustine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Prices for a cancer drug called lomustine have skyrocketed nearly 1,400 percent since 2013, putting a potentially life-saving treatment out of reach for patients suffering from brain tumors and ...

When the sole manufacturer withdrew a critical cancer drug from Medicare and Medicaid, patients were left without options. Policy makers must act to ensure that essential drugs remain affordable and ...

Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms In order to evaluate the impact of lomustine in a ...

Discover comprehensive details about Lomustine, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Further Evaluation of Intensified and Increased Total Dose of Cyclophosphamide for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-25 ...

Although the success of auto-HSCT depends on several variables, the lower the toxicity and the duration of neutropenia the smaller the treatment-related mortality. Given that lomustine has low ...